Floatz logo

dn-101

Hypophosphatemic Rickets

Massachusetts General HospitalSmall moleculeEarly Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Hypophosphatemic Rickets cohort.

Asset / SponsorPhaseRating
Burosumab
Redwood Dermatology Sciences
Phase 3BB

Same molecule, other indications

dn-101 is also rated in:

Friedreich AtaxiaDormant
B
Indicative ·
62 / 100
View asset →
PsoriasisDormant
B
Indicative ·
59 / 100
View asset →
Facial AngiofibromaDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →